Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

The global pipeline of cell therapies for cancer

  1. Jia Xin Yu

    1. Cancer Research Institute, New York, NY, USA.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  2. Vanessa M. Hubbard-Lucey

    1. Cancer Research Institute, New York, NY, USA.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  3. Jun Tang

    1. Cancer Research Institute, New York, NY, USA.

    View author publications

    You can also search for this author in PubMed  Google Scholar

The recent FDA approvals of pioneering cell therapies to treat CD19-positive haematological cancers have encouraged substantial R&D efforts with cell therapies in oncology. Indeed, cell therapies now represent the largest number of active agents in development in the immuno-oncology field overall (Nat. Rev. Drug Discov. 17, 783–784; 2018). In this article, we describe the latest development pipeline of cell therapies for cancer and the number of clinical trials for such agents, and we also compare the current landscape survey conducted in March 2019 with our previous one performed in March 2018 (Nat. Rev. Drug Discov. 17, 465–466; 2018).

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

Buy

All prices are NET prices.

Nature Reviews Drug Discovery 18, 821-822 (2019)

doi: https://doi.org/10.1038/d41573-019-00090-z

Updates & Corrections

  • Clarification 09 September 2019: In addition to the trials of agents included in Figure 1, there is an ongoing phase III trial of tumour-infiltrating lymphocytes in patients with melanoma sponsored by The Netherlands Cancer Institute (NCT02278887), which is included in Supplementary Figure 4.

Supplementary Information

  1. Supplementary information

Competing Interests

The authors declare no competing interests.

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links